{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:34:59Z","timestamp":1794411299278,"version":"4.9.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T00:00:00Z","timestamp":1640044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Though the disease burden of varicella in Europe has been reported previously, the economic burden is still unknown. This study estimated the economic burden of varicella in Europe in the absence of Universal Varicella Vaccination (UVV) in 2018 Euros from both payer (direct costs) and societal (direct and indirect costs) perspectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We estimated the country specific and overall annual costs of varicella in absence of UVV in 31 European countries (27 EU countries, plus Iceland, Norway, Switzerland and the United Kingdom). To obtain country specific unit costs and associated healthcare utilization, we conducted a systematic literature review, searching in PubMed, EMBASE, NEED, DARE, REPEC, Open Grey, and public heath websites (1\/1\/1999\u201310\/15\/2019). The number of annual varicella cases, deaths, outpatient visits and hospitalizations were calculated (without UVV) based on age-specific incidence rates (Riera-Montes et al. 2017) and 2018 population data by country. Unit cost per varicella case and disease burden data were combined using stochastic modeling to estimate 2018 costs stratified by country, age and healthcare resource.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall annual total costs associated with varicella were estimated to be \u20ac662,592,061 (Range: \u20ac309,552,363 to \u20ac1,015,631,760) in Europe in absence of UVV. Direct and indirect costs were estimated at \u20ac229,076,206 (Range \u20ac144,809,557 to \u20ac313,342,856) and \u20ac433,515,855 (Range \u20ac164,742,806 to \u20ac702,288,904), respectively. Total cost per case was \u20ac121.45 (direct: \u20ac41.99; indirect: \u20ac79.46). Almost half of the costs were attributed to cases in children under 5\u2009years, owing mainly to caregiver work loss. The distribution of costs by healthcare resource was similar across countries. France and Germany accounted for 49.28% of total annual costs, most likely due to a combination of high numbers of cases and unit costs in these countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The economic burden of varicella across Europe in the absence of UVV is substantial (over 600\u2009M\u20ac), primarily driven by caregiver burden including work productivity losses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12889-021-12343-x","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T23:29:30Z","timestamp":1640042970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Economic burden of varicella in Europe in the absence of universal varicella vaccination"],"prefix":"10.1186","volume":"21","author":[{"given":"Manjiri","family":"Pawaskar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estelle","family":"M\u00e9roc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salome","family":"Samant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmira","family":"Flem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Bencina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Riera-Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Heininger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,21]]},"reference":[{"issue":"3","key":"12343_CR1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1128\/CMR.9.3.361","volume":"9","author":"AM Arvin","year":"1996","unstructured":"Arvin AM. Varicella-zoster virus. Clin Microbiol Rev. 1996;9(3):361\u201381.","journal-title":"Clin Microbiol Rev"},{"issue":"9544","key":"12343_CR2","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S0140-6736(06)69561-5","volume":"368","author":"U Heininger","year":"2006","unstructured":"Heininger U, Seward JF. Varicella. Lancet. 2006;368(9544):1365\u201376.","journal-title":"Lancet"},{"key":"12343_CR3","volume-title":"Varicella vaccination in the European Union","author":"ECDC","year":"2015","unstructured":"ECDC. Varicella vaccination in the European Union. Stockholm: ECDC GUIDANCE nwww.ecdc.europa.eu; 2015."},{"issue":"1","key":"12343_CR4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s12879-017-2445-2","volume":"17","author":"M Riera-Montes","year":"2017","unstructured":"Riera-Montes M, et al. Estimation of the burden of varicella in Europe before the introduction of universal childhood immunization. BMC Infect Dis. 2017;17(1):353.","journal-title":"BMC Infect Dis"},{"issue":"1","key":"12343_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s10198-003-0200-7","volume":"5","author":"K Banz","year":"2004","unstructured":"Banz K, et al. The burden of varicella in Germany. Potential risks and economic impact. Eur J Health Econ. 2004;5(1):46\u201353.","journal-title":"Eur J Health Econ"},{"key":"12343_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2005.04005.x","volume-title":"The economic value of childhood varicella vaccination in France and Germany","author":"L Coudeville","year":"2005","unstructured":"Coudeville, L., et al., The economic value of childhood varicella vaccination in France and Germany. 2005, HAL"},{"issue":"7","key":"12343_CR7","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00038-016-0842-8","volume":"61","author":"O Damm","year":"2016","unstructured":"Damm O, et al. Epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany: a systematic review. Int J Public Health. 2016;61(7):847\u201360.","journal-title":"Int J Public Health"},{"issue":"23","key":"12343_CR8","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1016\/S0264-410X(03)00264-0","volume":"21","author":"J D\u00edez-Domingo","year":"2003","unstructured":"D\u00edez-Domingo J, et al. Epidemiology and economic impact of varicella in immunocompetent children in Spain. A nation-wide study. Vaccine. 2003;21(23):3236\u20139.","journal-title":"Vaccine"},{"issue":"29","key":"12343_CR9","doi-asserted-by":"publisher","first-page":"3779","DOI":"10.1016\/j.vaccine.2019.05.063","volume":"37","author":"H Haugnes","year":"2019","unstructured":"Haugnes H, Flem E, Wisl\u00f8ff T. Healthcare costs associated with varicella and herpes zoster in Norway. Vaccine. 2019;37(29):3779\u201384.","journal-title":"Vaccine"},{"issue":"25","key":"12343_CR10","first-page":"265","volume":"89","author":"WHO","year":"2014","unstructured":"WHO. Varicella and herpes zoster vaccines: WHO position paper, June 2014. Wkly Epidemiol Rec. 2014;89(25):265\u201387.","journal-title":"Wkly Epidemiol Rec"},{"issue":"2","key":"12343_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/INF.0000000000002233","volume":"38","author":"V Spoulou","year":"2019","unstructured":"Spoulou V, et al. Implementing universal varicella vaccination in Europe: the path forward. Pediatr Infect Dis J. 2019;38(2):181\u20138.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"12343_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4161\/hv.34311","volume":"11","author":"A Bechini","year":"2015","unstructured":"Bechini A, et al. Impact of universal vaccination against varicella in Italy: experiences from eight Italian regions. Hum Vaccin Immunother. 2015;11(1):63\u201371.","journal-title":"Hum Vaccin Immunother"},{"key":"12343_CR13","volume-title":"Vaccine schedules in all countries of the European Union","author":"ECDC","year":"2020","unstructured":"ECDC, Vaccine schedules in all countries of the European Union. 2020. https:\/\/vaccine-schedule.ecdc.europa.eu\/."},{"key":"12343_CR14","first-page":"1","volume-title":"Cost-of-illness studies\u2014a primer. RTI-UNC Center of Excellence in Health Promotion Economics","author":"JE Segel","year":"2006","unstructured":"Segel JE. Cost-of-illness studies\u2014a primer. RTI-UNC Center of Excellence in Health Promotion Economics; 2006. p. 1\u201339."},{"issue":"7","key":"12343_CR15","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.","journal-title":"PLoS Med"},{"key":"12343_CR16","unstructured":"Eurostat, Eurostat GDP data. https:\/\/ec.europa.eu\/eurostat\/web\/national-accounts\/data\/database 2019."},{"key":"12343_CR17","unstructured":"Eurostat, Eurostat PPP data. https:\/\/ec.europa.eu\/eurostat\/web\/purchasing-power-parities\/data\/database 2019."},{"issue":"12","key":"12343_CR18","doi-asserted-by":"publisher","first-page":"847","DOI":"10.4161\/hv.9898","volume":"5","author":"K Banz","year":"2009","unstructured":"Banz K, et al. Economic evaluation of varicella vaccination in Swiss children and adolescents. Hum Vaccin. 2009;5(12):847\u201357.","journal-title":"Hum Vaccin"},{"issue":"3","key":"12343_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/j.1524-4733.2005.04005.x","volume":"8","author":"L Coudeville","year":"2005","unstructured":"Coudeville L, et al. The economic value of childhood varicella vaccination in France and Germany. Value Health. 2005;8(3):209\u201322.","journal-title":"Value Health"},{"issue":"25\u201326","key":"12343_CR20","doi-asserted-by":"publisher","first-page":"3614","DOI":"10.1016\/S0264-410X(03)00405-5","volume":"21","author":"T Hanslik","year":"2003","unstructured":"Hanslik T, et al. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. Vaccine. 2003;21(25\u201326):3614\u201322.","journal-title":"Vaccine"},{"issue":"4","key":"12343_CR21","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.clinthera.2015.01.006","volume":"37","author":"KJ Littlewood","year":"2015","unstructured":"Littlewood KJ, et al. Cost-effectiveness of routine varicella vaccination using the measles, mumps, rubella and varicella vaccine in France: an economic analysis based on a dynamic transmission model for varicella and herpes zoster. Clin Ther. 2015;37(4):830\u201341.","journal-title":"Clin Ther"},{"issue":"5","key":"12343_CR22","first-page":"432","volume":"115","author":"GP Blasco","year":"2017","unstructured":"Blasco GP, Blasco P\u00e9rez-Aramend\u00eda J. A cost-benefit analysis of varicella vaccination in Arag\u00f3n. Arch Argent Pediatr. 2017;115(5):432\u20138.","journal-title":"Arch Argent Pediatr"},{"issue":"11\u201312","key":"12343_CR23","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/S0264-410X(98)00394-6","volume":"17","author":"J D\u00edez Domingo","year":"1999","unstructured":"D\u00edez Domingo J, et al. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine. 1999;17(11\u201312):1306\u201311.","journal-title":"Vaccine"},{"issue":"1","key":"12343_CR24","first-page":"115","volume":"23","author":"T Forc\u00e9n","year":"2000","unstructured":"Forc\u00e9n T, et al. Economic evaluation of routine vaccination of 15 month old children against chicken-pox-zoster. An Sist Sanit Navar. 2000;23(1):115\u201324.","journal-title":"An Sist Sanit Navar"},{"issue":"47\u201348","key":"12343_CR25","doi-asserted-by":"publisher","first-page":"6980","DOI":"10.1016\/j.vaccine.2006.04.051","volume":"24","author":"X Lenne","year":"2006","unstructured":"Lenne X, et al. Economic evaluation of varicella vaccination in Spain-results from a dynamic model. Vaccine. 2006;24(47\u201348):6980\u20139.","journal-title":"Vaccine"},{"issue":"4","key":"12343_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0213-9111(04)72015-4","volume":"18","author":"I Pe\u00f1a-Rey","year":"2004","unstructured":"Pe\u00f1a-Rey I, et al. Cost-effectiveness of varicella vaccination in Spanish adolescents. Gac Sanit. 2004;18(4):287\u201394.","journal-title":"Gac Sanit"},{"issue":"1","key":"12343_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1590\/S1135-57272008000100009","volume":"82","author":"A P\u00e9rez-Rubio","year":"2008","unstructured":"P\u00e9rez-Rubio A, et al. Social and economic impact of chicken pox vaccine at 15 months of age. Castile and Leon, Spain, 2004. Rev Esp Salud Publica. 2008;82(1):101\u20139.","journal-title":"Rev Esp Salud Publica"},{"issue":"29\u201330","key":"12343_CR28","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1016\/j.vaccine.2004.03.048","volume":"22","author":"P Plans-Rubi\u00f3","year":"2004","unstructured":"Plans-Rubi\u00f3 P. Critical prevalence of antibodies minimizing vaccination costs for hepatitis a, hepatitis B, varicella, measles and tetanus in adults and adolescents in Catalonia. Spain Vaccine. 2004;22(29\u201330):4002\u201313.","journal-title":"Spain Vaccine"},{"issue":"3","key":"12343_CR29","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S0213-9111(03)71728-2","volume":"17","author":"FJ Valad\u00e9s","year":"2003","unstructured":"Valad\u00e9s FJ, et al. Chickenpox outbreak in Herrera del Duque, Badajoz, Spain. Gac Sanit. 2003;17(3):196\u2013203.","journal-title":"Gac Sanit"},{"issue":"1","key":"12343_CR30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s12879-017-2575-6","volume":"17","author":"Z Meszner","year":"2017","unstructured":"Meszner Z, et al. Economic burden of varicella in children 1-12 years of age in Hungary, 2011-2015. BMC Infect Dis. 2017;17(1):495.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"12343_CR31","first-page":"33","volume":"12","author":"LE Gialloreti","year":"2005","unstructured":"Gialloreti LE, et al. Analysis of the cost-effectiveness of varicella vaccine programmes based on an observational survey in the Latium region of Italy. Herpes. 2005;12(2):33\u20137.","journal-title":"Herpes"},{"issue":"27\u201328","key":"12343_CR32","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1016\/j.vaccine.2004.03.043","volume":"22","author":"N Thiry","year":"2004","unstructured":"Thiry N, et al. An economic evaluation of varicella vaccination in Italian adolescents. Vaccine. 2004;22(27\u201328):3546\u201362.","journal-title":"Vaccine"},{"issue":"37\u201339","key":"12343_CR33","doi-asserted-by":"publisher","first-page":"6288","DOI":"10.1016\/j.vaccine.2006.05.071","volume":"24","author":"HJ Boot","year":"2006","unstructured":"Boot HJ, et al. Assessing the introduction of universal varicella vaccination in the Netherlands. Vaccine. 2006;24(37\u201339):6288\u201399.","journal-title":"Vaccine"},{"issue":"1","key":"12343_CR34","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1186\/s12889-018-5298-8","volume":"18","author":"J Wysocki","year":"2018","unstructured":"Wysocki J, et al. Varicella in Poland: economic burden in children 1-12 years of age in Poland, 2010-2015. BMC Public Health. 2018;18(1):410.","journal-title":"BMC Public Health"},{"issue":"10","key":"12343_CR35","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1136\/adc.88.10.862","volume":"88","author":"M Brisson","year":"2003","unstructured":"Brisson M, Edmunds WJ. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child. 2003;88(10):862\u20139.","journal-title":"Arch Dis Child"},{"issue":"9","key":"12343_CR36","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.vaccine.2005.09.028","volume":"24","author":"A Pinot De Moira","year":"2006","unstructured":"Pinot De Moira A, Edmunds WJ, Breuer J. The cost-effectiveness of antenatal varicella screening with post-partum vaccination of susceptibles. Vaccine. 2006;24(9):1298\u2013307.","journal-title":"Vaccine"},{"issue":"6","key":"12343_CR37","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/j.vaccine.2011.11.026","volume":"30","author":"AJ Van Hoek","year":"2012","unstructured":"Van Hoek AJ, et al. The cost-effectiveness of varicella and combined varicella and herpes zoster vaccination programmes in the United Kingdom. Vaccine. 2012;30(6):1225\u201334.","journal-title":"Vaccine"},{"issue":"11","key":"12343_CR38","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1017\/S0950268811002640","volume":"140","author":"J Bilcke","year":"2012","unstructured":"Bilcke J, et al. The health and economic burden of chickenpox and herpes zoster in Belgium. Epidemiol Infect. 2012;140(11):2096\u2013109.","journal-title":"Epidemiol Infect"},{"issue":"4","key":"12343_CR39","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1055\/s-2005-836610","volume":"218","author":"M Knuf","year":"2006","unstructured":"Knuf M, Nei\u00df A, Wutzler P. Impact of universal varicella vaccination in Germany: an epidemiological and economic analysis. Klinische Padiatrie. 2006;218(4):203\u201312.","journal-title":"Klinische Padiatrie"},{"issue":"7","key":"12343_CR40","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1023\/B:EJEP.0000036791.43264.84","volume":"19","author":"\u00c1 Gil","year":"2004","unstructured":"Gil \u00c1, et al. The burden of severe varicella in Spain, 1995-2000 period. Eur J Epidemiol. 2004;19(7):699\u2013702.","journal-title":"Eur J Epidemiol"},{"issue":"3\u20134","key":"12343_CR41","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/S0264-410X(01)00370-X","volume":"20","author":"A Gil","year":"2001","unstructured":"Gil A, et al. Epidemiology of primary varicella hospitalizations in Spain. Vaccine. 2001;20(3\u20134):295\u20138.","journal-title":"Vaccine"},{"issue":"3","key":"12343_CR42","first-page":"259","volume":"50","author":"MR G\u00f3mez","year":"1999","unstructured":"G\u00f3mez MR, et al. Complications of varicella in children. An Esp Pediatr. 1999;50(3):259\u201362.","journal-title":"An Esp Pediatr"},{"issue":"8","key":"12343_CR43","doi-asserted-by":"publisher","first-page":"659","DOI":"10.4161\/hv.6.8.12014","volume":"6","author":"JM Guillen","year":"2010","unstructured":"Guillen JM, et al. Burden of adult varicella hospitalizations in Spain (2001-2007). Human Vaccines. 2010;6(8):659\u201363.","journal-title":"Human Vaccines"},{"issue":"9","key":"12343_CR44","first-page":"32","volume":"26","author":"JM Guill\u00e9n","year":"2006","unstructured":"Guill\u00e9n JM, et al. Paediatric hospitalizations attributable to varicella zoster virus infections. Pediatrika. 2006;26(9):32\u20137.","journal-title":"Pediatrika"},{"issue":"2","key":"12343_CR45","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1157\/13077453","volume":"63","author":"AI Piqueras Arenas","year":"2005","unstructured":"Piqueras Arenas AI, et al. Hospitalizations for varicella in the Hospital Infantil La Fe, Valencia,Spain, 2001-2004. An Pediatr. 2005;63(2):120\u20134.","journal-title":"An Pediatr"},{"issue":"2","key":"12343_CR46","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0264-410X(98)00161-3","volume":"17","author":"L Coudeville","year":"1999","unstructured":"Coudeville L, et al. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine. 1999;17(2):142\u201351.","journal-title":"Vaccine"},{"issue":"9","key":"12343_CR47","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0929-693X(04)00410-5","volume":"11","author":"E Mallet","year":"2004","unstructured":"Mallet E, et al. Evaluation of varicella complications through a retrospective hospital survey in a paediatric center over 16 years in France. Arch Pediatr. 2004;11(9):1145\u201351.","journal-title":"Arch Pediatr"},{"issue":"12","key":"12343_CR48","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1185\/030079907X242610","volume":"23","author":"C Azzari","year":"2007","unstructured":"Azzari C, et al. Cost of varicella-related hospitalisations in an Italian paediatric hospital: comparison with possible vaccination expenses. Curr Med Res Opin. 2007;23(12):2945\u201354.","journal-title":"Curr Med Res Opin"},{"issue":"44","key":"12343_CR49","doi-asserted-by":"publisher","first-page":"5619","DOI":"10.1016\/j.vaccine.2008.07.096","volume":"26","author":"P Bonanni","year":"2008","unstructured":"Bonanni P, et al. Economic evaluation of varicella vaccination in Italian children and adolescents according to different intervention strategies: the burden of uncomplicated hospitalised cases. Vaccine. 2008;26(44):5619\u201326.","journal-title":"Vaccine"},{"issue":"3","key":"12343_CR50","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.jinf.2016.05.008","volume":"73","author":"PHF Hobbelen","year":"2016","unstructured":"Hobbelen PHF, et al. The burden of hospitalisation for varicella and herpes zoster in England from 2004 to 2013. J Infect. 2016;73(3):241\u201353.","journal-title":"J Infect"},{"issue":"1","key":"12343_CR51","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1136\/archdischild-2015-308283","volume":"101","author":"S Blumental","year":"2016","unstructured":"Blumental S, et al. Varicella paediatric hospitalisations in Belgium: a 1-year national survey. Arch Dis Child. 2016;101(1):16\u201322.","journal-title":"Arch Dis Child"},{"issue":"6","key":"12343_CR52","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1007\/s00431-005-1637-8","volume":"164","author":"J Bonhoeffer","year":"2005","unstructured":"Bonhoeffer J, et al. Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents. Eur J Pediatr. 2005;164(6):366\u201370.","journal-title":"Eur J Pediatr"},{"issue":"3","key":"12343_CR53","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S1294-5501(06)70812-3","volume":"8","author":"V Maresova","year":"2006","unstructured":"Maresova V, et al. Varicella and its complications: a five-year retrospective analysis of hospitalized patients. Antibiotiques. 2006;8(3):131\u20135.","journal-title":"Antibiotiques"},{"issue":"13","key":"12343_CR54","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1017\/S0950268817001777","volume":"145","author":"IG Helmuth","year":"2017","unstructured":"Helmuth IG, Poulsen A, M\u00f8lbak K. A national register-based study of paediatric varicella hospitalizations in Denmark 2010-2016. Epidemiol Infect. 2017;145(13):2683\u201393.","journal-title":"Epidemiol Infect"},{"issue":"2","key":"12343_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/INF.0b013e3181586665","volume":"27","author":"JG Liese","year":"2008","unstructured":"Liese JG, et al. The burden of varicella complications before the introduction of routine varicella vaccination in Germany. Pediatr Infect Dis J. 2008;27(2):119\u201324.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"12343_CR56","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/INF.0000000000001356","volume":"36","author":"A Streng","year":"2017","unstructured":"Streng A, et al. Decline of neurologic varicella complications in children during the first seven years after introduction of universal varicella vaccination in Germany, 2005-2011. Pediatr Infect Dis J. 2017;36(1):79\u201386.","journal-title":"Pediatr Infect Dis J"},{"issue":"2","key":"12343_CR57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00430-002-0123-4","volume":"191","author":"P Wutzler","year":"2002","unstructured":"Wutzler P, et al. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella immunisation in Germany. Med Microbiol Immunol. 2002;191(2):89\u201396.","journal-title":"Med Microbiol Immunol"},{"issue":"4","key":"12343_CR58","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s00431-005-0043-6","volume":"165","author":"M Theodoridou","year":"2006","unstructured":"Theodoridou M, et al. Varicella-related complications and hospitalisations in a tertiary pediatric medical center before vaccine introduction. Eur J Pediatr. 2006;165(4):273\u20134.","journal-title":"Eur J Pediatr"},{"issue":"3","key":"12343_CR59","first-page":"101","volume":"63","author":"P Gonz\u00e1lez Santiago","year":"2005","unstructured":"Gonz\u00e1lez Santiago P, et al. Hospital admission due to varicella: A retrospective study. Acta Pediatr Esp. 2005;63(3):101\u20134.","journal-title":"Acta Pediatr Esp"},{"issue":"4","key":"12343_CR60","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1017\/S0950268808001131","volume":"137","author":"JM Guill\u00e9n","year":"2009","unstructured":"Guill\u00e9n JM, et al. Varicella paediatric hospitalizations in Spain. Epidemiol Infect. 2009;137(4):519\u201325.","journal-title":"Epidemiol Infect"},{"issue":"5","key":"12343_CR61","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1590\/S1135-57272009000500012","volume":"83","author":"I Pe\u00f1a-Rey","year":"2009","unstructured":"Pe\u00f1a-Rey I, et al. Epidemiology of varicella in Spain pre-and post-vaccination periods. Rev Esp Salud Publica. 2009;83(5):711\u201324.","journal-title":"Rev Esp Salud Publica"},{"issue":"3","key":"12343_CR62","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S1695-4033(03)78170-3","volume":"59","author":"EG P\u00e9rez-Yarza","year":"2003","unstructured":"P\u00e9rez-Yarza EG, et al. Hospital admissions for varicella complications in children aged less than 15 years old. An Pediatr. 2003;59(3):229\u201333.","journal-title":"An Pediatr"},{"issue":"1","key":"12343_CR63","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1017\/S0950268806006467","volume":"135","author":"F Dubos","year":"2007","unstructured":"Dubos F, et al. Epidemiology of hospital admissions for paediatric varicella infections: a one-year prospective survey in the pre-vaccine era. Epidemiol Infect. 2007;135(1):131\u20138.","journal-title":"Epidemiol Infect"},{"issue":"2","key":"12343_CR64","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.medmal.2005.12.001","volume":"36","author":"C Emery","year":"2006","unstructured":"Emery C, et al. ENVOL study on the medical management of varicella and its complications in French ambulatory care. Med Mal Infect. 2006;36(2):92\u20138.","journal-title":"Med Mal Infect"},{"issue":"5","key":"12343_CR65","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/j.1469-0691.2007.01706.x","volume":"13","author":"E Grimprel","year":"2007","unstructured":"Grimprel E, et al. Paediatric varicella hospitalisations in France: a nationwide survey. Clin Microbiol Infect. 2007;13(5):546\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"12343_CR66","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s00431-010-1212-9","volume":"169","author":"A L\u00e9cuyer","year":"2010","unstructured":"L\u00e9cuyer A, et al. Hospitalization of newborns and young infants for chickenpox in France. Eur J Pediatr. 2010;169(10):1293\u20137.","journal-title":"Eur J Pediatr"},{"issue":"5","key":"12343_CR67","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.arcped.2006.01.025","volume":"13","author":"A Mandelcwajg","year":"2006","unstructured":"Mandelcwajg A, et al. Causes of hospitalization of patients with ongoing varicella in a French children hospital: evolution between 1990 and 2001. Arch Pediatr. 2006;13(5):429\u201335.","journal-title":"Arch Pediatr"},{"issue":"4","key":"12343_CR68","first-page":"169","volume":"46","author":"L Bertoluzzo","year":"2005","unstructured":"Bertoluzzo L, et al. The hospitalization because of varicella in a tertiary care pediatric hospital during 10 year study period. J Prev Med Hygiene. 2005;46(4):169\u201372.","journal-title":"J Prev Med Hygiene"},{"issue":"11","key":"12343_CR69","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1099\/jmm.0.000061","volume":"64","author":"C Trucchi","year":"2015","unstructured":"Trucchi C, et al. Burden of varicella in Italy, 2001\u20132010: analysis of data from multiple sources and assessment of universal vaccination impact in three pilot regions. J Med Microbiol. 2015;64(11):1387\u201394.","journal-title":"J Med Microbiol"},{"key":"12343_CR70","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/1471-2334-11-320","volume":"11","author":"JH Wolleswinkel-van den Bosch","year":"2011","unstructured":"Wolleswinkel-van den Bosch JH, et al. The burden of varicella from a parent's perspective and its societal impact in The Netherlands: an Internet survey. BMC Infect Dis. 2011;11:320.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"12343_CR71","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1097\/INF.0000000000001656","volume":"36","author":"G Mirinaviciute","year":"2017","unstructured":"Mirinaviciute G, et al. Varicella-related primary health-care visits, hospitalizations and mortality in Norway, 2008-2014. Pediatr Infect Dis J. 2017;36(11):1032\u20138.","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"12343_CR72","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1016\/j.ijid.2012.11.024","volume":"17","author":"E Gowin","year":"2013","unstructured":"Gowin E, Wysocki J, Michalak M. Don't forget how severe varicella can be-complications of varicella in children in a defined polish population. Int J Infect Dis. 2013;17(7):e485\u20139.","journal-title":"Int J Infect Dis"},{"key":"12343_CR73","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ijid.2017.07.009","volume":"62","author":"E Gowin","year":"2017","unstructured":"Gowin E, et al. Too young to be vaccinated: hospitalizations caused by varicella among children in the first year of life. Int J Infect Dis. 2017;62:52\u20135.","journal-title":"Int J Infect Dis"},{"issue":"Suppl 1","key":"12343_CR74","first-page":"134","volume":"58","author":"E Smukalska","year":"2004","unstructured":"Smukalska E, Dura B. Complications of chickenpox as reason for children's hospitalization. Przegl Epidemiol. 2004;58(Suppl 1):134\u20138.","journal-title":"Przegl Epidemiol"},{"issue":"2","key":"12343_CR75","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/INF.0000000000000969","volume":"35","author":"CP Popescu","year":"2016","unstructured":"Popescu CP, et al. Complications of varicella in unvaccinated children from Romania, 2002-2013: a retrospective study. Pediatr Infect Dis J. 2016;35(2):211\u20132.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"12343_CR76","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1186\/s12879-016-1957-5","volume":"16","author":"K Widgren","year":"2016","unstructured":"Widgren K, et al. The burden of chickenpox disease in Sweden. BMC Infect Dis. 2016;16(1):666.","journal-title":"BMC Infect Dis"},{"issue":"5","key":"12343_CR77","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1469-0691.2004.00853.x","volume":"10","author":"S Wagenpfeil","year":"2004","unstructured":"Wagenpfeil S, et al. Empirical data on the varicella situation in Germany for vaccinatin decisions. Clin Microbiol Infect. 2004;10(5):425\u201330.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"12343_CR78","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1097\/00006454-199905000-00004","volume":"18","author":"P Fornaro","year":"1999","unstructured":"Fornaro P, et al. Epidemiology and cost analysis of varicella in Italy: results of a sentinel study in the pediatric practice. Pediatr Infect Dis J. 1999;18(5):414\u20139.","journal-title":"Pediatr Infect Dis J"},{"issue":"28","key":"12343_CR79","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1016\/j.vaccine.2014.04.034","volume":"32","author":"A Van Lier","year":"2014","unstructured":"Van Lier A, et al. Low varicella-related consultation rate in the Netherlands in primary care data. Vaccine. 2014;32(28):3517\u201324.","journal-title":"Vaccine"},{"issue":"5","key":"12343_CR80","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00431-019-03332-9","volume":"178","author":"Y Rodriguez-Santana","year":"2019","unstructured":"Rodriguez-Santana Y, et al. Epidemiological and clinical characteristics and the approach to infant chickenpox in primary care. Eur J Pediatr. 2019;178(5):641\u20138.","journal-title":"Eur J Pediatr"},{"issue":"8","key":"12343_CR81","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1097\/00006454-200208000-00008","volume":"21","author":"A Volpi","year":"2002","unstructured":"Volpi A, et al. Antiviral treatment of varicella in pediatric practice in the latium region of Italy: results of an observational study. Pediatr Infect Dis J. 2002;21(8):739\u201342.","journal-title":"Pediatr Infect Dis J"},{"key":"12343_CR82","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/1471-2334-12-110","volume":"12","author":"JG Pierik","year":"2012","unstructured":"Pierik JG, et al. Epidemiological characteristics and societal burden of varicella zoster virus in the Netherlands. BMC Infect Dis. 2012;12:110.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"12343_CR83","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1586\/14760584.7.6.753","volume":"7","author":"MH Rozenbaum","year":"2008","unstructured":"Rozenbaum MH, et al. Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Rev Vaccines. 2008;7(6):753\u201382.","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"12343_CR84","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1542\/peds.78.4.728","volume":"78","author":"SR Preblud","year":"1986","unstructured":"Preblud SR. Varicella: complications and costs. Pediatrics. 1986;78(4):728\u201335.","journal-title":"Pediatrics"},{"key":"12343_CR85","unstructured":"Eurostat, Minimum wage statistics. https:\/\/ec.europa.eu\/eurostat\/statistics-explained\/index.php\/Minimum_wage_statistics#General_overview, 2018."},{"issue":"5","key":"12343_CR86","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/01.inf.0000122606.88429.8f","volume":"23","author":"B Rentier","year":"2004","unstructured":"Rentier B, Gershon AA. Consensus: varicella vaccination of healthy children - a challenge for Europe. Pediatr Infect Dis J. 2004;23(5):379\u201389.","journal-title":"Pediatr Infect Dis J"},{"issue":"13","key":"12343_CR87","doi-asserted-by":"publisher","first-page":"839","DOI":"10.2165\/00019053-200422130-00003","volume":"22","author":"L Coudeville","year":"2004","unstructured":"Coudeville L, et al. Varicella vaccination in Italy: an economic evaluation of different scenarios. Pharmacoeconomics. 2004;22(13):839\u201355.","journal-title":"Pharmacoeconomics"},{"key":"12343_CR88","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/CEOR.S229685","volume":"12","author":"C Azzari","year":"2020","unstructured":"Azzari C, et al. The cost-effectiveness of universal varicella vaccination in Italy: a model-based assessment of vaccination strategies. Clinicoecon Outcomes Res. 2020;12:273\u201383.","journal-title":"Clinicoecon Outcomes Res"},{"issue":"8","key":"12343_CR89","doi-asserted-by":"publisher","first-page":"e0220921","DOI":"10.1371\/journal.pone.0220921","volume":"14","author":"LJ Wolfson","year":"2019","unstructured":"Wolfson LJ, et al. Cost-effectiveness analysis of universal varicella vaccination in Turkey using a dynamic transmission model. PLoS One. 2019;14(8):e0220921.","journal-title":"PLoS One"},{"key":"12343_CR90","doi-asserted-by":"crossref","unstructured":"Akpo EI, Cristeau O, Hunjan M, Casabona G. Epidemiological Impact and Cost-Effectiveness of Varicella Vaccination Strategies in the United Kingdom. Clin Infect Dis. 2021;73(11):e3617\u201326.","DOI":"10.1093\/cid\/ciaa1708"},{"key":"12343_CR91","volume-title":"Varicella National Immunization Program in Denmark in ISPOR Europe 2020 (virtual)","author":"M Pawaskar","year":"2019","unstructured":"Pawaskar, M., et al. Varicella National Immunization Program in Denmark in ISPOR Europe 2020 (virtual). 2019."},{"issue":"3","key":"12343_CR92","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1017\/S0950268800004714","volume":"125","author":"M Brisson","year":"2000","unstructured":"Brisson M, et al. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect. 2000;125(3):651\u201369.","journal-title":"Epidemiol Infect"},{"issue":"1","key":"12343_CR93","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s12889-015-1861-8","volume":"15","author":"O Damm","year":"2015","unstructured":"Damm O, et al. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. BMC Public Health. 2015;15(1):533.","journal-title":"BMC Public Health"},{"issue":"7","key":"12343_CR94","first-page":"1766","volume":"12","author":"J Horn","year":"2016","unstructured":"Horn J, et al. Current and future effects of varicella and herpes zoster vaccination in Germany \u2013 insights from a mathematical model in a country with universal varicella vaccination. Hum Vaccin Immunother. 2016;12(7):1766\u201376.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"12343_CR95","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s11517-018-1938-5","volume":"57","author":"M Betta","year":"2019","unstructured":"Betta M, et al. Models for optimally controlling varicella and herpes zoster by varicella vaccination: a comparative study. Med Biol Eng Comput. 2019;57(5):1121\u201332.","journal-title":"Med Biol Eng Comput"},{"issue":"8","key":"12343_CR96","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1080\/14760584.2019.1646129","volume":"18","author":"R Harpaz","year":"2019","unstructured":"Harpaz R. Do varicella vaccination programs change the epidemiology of herpes zoster? A comprehensive review, with focus on the United States. Expert Rev Vaccin. 2019;18(8):793\u2013811.","journal-title":"Expert Rev Vaccin"},{"issue":"1","key":"12343_CR97","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12879-019-3759-z","volume":"19","author":"C Sauboin","year":"2019","unstructured":"Sauboin C, et al. The impact of childhood varicella vaccination on the incidence of herpes zoster in the general population: modelling the effect of exogenous and endogenous varicella-zoster virus immunity boosting. BMC Infect Dis. 2019;19(1):126.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"12343_CR98","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1093\/infdis\/jit405","volume":"208","author":"S Weinmann","year":"2013","unstructured":"Weinmann S, et al. Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005\u20132009. J Infect Dis. 2013;208(11):1859\u201368.","journal-title":"J Infect Dis"},{"issue":"1","key":"12343_CR99","doi-asserted-by":"publisher","first-page":"e20182917","DOI":"10.1542\/peds.2018-2917","volume":"144","author":"S Weinmann","year":"2019","unstructured":"Weinmann S, et al. Incidence of herpes zoster among children: 2003\u20132014. Pediatrics. 2019;144(1):e20182917.","journal-title":"Pediatrics"},{"issue":"11","key":"12343_CR100","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1080\/14760584.2018.1538801","volume":"17","author":"SE Talbird","year":"2018","unstructured":"Talbird SE, et al. Understanding the role of exogenous boosting in modeling varicella vaccination. Expert Rev Vaccin. 2018;17(11):1021\u201335.","journal-title":"Expert Rev Vaccin"},{"issue":"13","key":"12343_CR101","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2165\/00019053-200422130-00004","volume":"22","author":"R Welte","year":"2004","unstructured":"Welte R, et al. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics. 2004;22(13):857\u201376.","journal-title":"Pharmacoeconomics"},{"key":"12343_CR102","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2471\/BLT.10.084087","volume":"90","author":"L Ni\u00ebns","year":"2012","unstructured":"Ni\u00ebns L, et al. Practical measurement of affordability: an application to medicines. Bull World Health Organ. 2012;90:219\u201327.","journal-title":"Bull World Health Organ"},{"issue":"1","key":"12343_CR103","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40545-016-0057-7","volume":"9","author":"P Petrou","year":"2016","unstructured":"Petrou P, Talias MA. Navigating through the maze of pricing and affordability of branded pharmaceuticals in the midst of the financial crisis: a comparative study among five European recession countries, from a Cyprus perspective. J Pharm Policy Pract. 2016;9(1):8.","journal-title":"J Pharm Policy Pract"},{"issue":"2","key":"12343_CR104","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0163-4453(03)00079-3","volume":"48","author":"G Ginsberg","year":"2004","unstructured":"Ginsberg G, Somekh E. Cost containment analysis of childhood vaccination against varicella in Israel. J Infect. 2004;48(2):119\u201333.","journal-title":"J Infect"},{"issue":"3","key":"12343_CR105","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s40273-015-0335-2","volume":"34","author":"B Ultsch","year":"2016","unstructured":"Ultsch B, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics. 2016;34(3):227\u201344.","journal-title":"Pharmacoeconomics"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-12343-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-021-12343-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-021-12343-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:04:15Z","timestamp":1666742655000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-021-12343-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,21]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["12343"],"URL":"https:\/\/doi.org\/10.1186\/s12889-021-12343-x","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,21]]},"assertion":[{"value":"25 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"M.P. and S.S. are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA and own stock in Merck & Co., Inc., Kenilworth, NJ, USA. E.F. is an employee of MSD Norway AS and owns stock in Merck & Co., Inc., Kenilworth, NJ, USA. G.B. is an employee of MSD Spain and owns stock in Merck & Co., Inc., Kenilworth, NJ, USA. E.M. and M.R. have received consulting fees from Merck & Co for this work. U.H. has joined a varicella advisory board with MSD Switzerland after this project had been completed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2312"}}